The Positive Data
EGFR exon 20 insertion mutations drive a distinct subset of non-small cell lung cancer, about 2 percent of cases, and they have historically responded poorly to the EGFR inhibitors that transformed the common EGFR mutations. The field's answer has been a new generation of drugs built specifically for the exon 20 shape, and the latest readout belongs to zipalertinib.
In the REZILIENT3 Phase 3 trial, presented at the World Conference on Lung Cancer in Seoul, zipalertinib plus platinum-based chemotherapy produced a median progression-free survival of 14.5 months versus 8.5 months for chemotherapy alone in the first-line setting. The hazard ratio was 0.50, a 50 percent reduction in the risk of progression or death, with a p-value of 0.00015. The objective response rate was 65.0 percent against 40.3 percent, and the benefit held across subgroups including patients with brain metastases, where the hazard ratio was 0.38.
The trial enrolled 279 patients after a safety lead-in, randomized to the combination or to chemotherapy alone. The partners, Cullinan Therapeutics and Taiho, will take the data to regulators for first-line discussions, building on an FDA application already under review for the second-line setting with a target action date of February 27, 2027.
The Market's Different Arithmetic
Cullinan shares fell about 6 percent on the news. On its face that reads as an error, a successful Phase 3 trial met with selling, but the market's math is comparative, and the comparator is formidable.
The standard against which every exon 20 regimen is now judged is amivantamab, the bispecific antibody that has defined first-line expectations. Cross-trial comparisons, imperfect but unavoidable, place zipalertinib's 14.5-month progression-free survival in a competitive range rather than a leading one, and the combination's safety profile, grade 3 or higher adverse events in 87.1 percent of patients versus 54.4 percent on chemotherapy alone, mostly hematologic, adds a tolerability question to the comparison.
The overall survival data are immature, with an interim hazard ratio of 0.72 and wide confidence intervals, and survival is the endpoint that settles debates in this disease. Analysts at Stifel, BTIG, UBS and TD Cowen maintained buy ratings, with price targets from $27 to $40, and peak sales estimates around a billion dollars, on the theory that a 50 percent progression-free survival improvement with an oral drug is a viable share of a market that will support several regimens.
Both readings can coexist. The data are positive and real. The stock move is a reminder that in oncology, statistical significance is priced against a moving bar set by the last great drug, not by the placebo arm.
What Changes for Patients
The practical effect is incremental and real. The first-line exon 20 field now has another candidate combination with published Phase 3 data, and if regulators agree, patients and oncologists gain an oral option to weigh against the infused alternatives. The FDA's second-line decision, due in February, will arrive first and will tell the market whether the drug clears the agency's bar before the first-line question is even asked.
The deeper story is about the standard of evidence in a fast-moving field. A year ago, a six-month progression-free survival gain would have been the lead of the conference. This week it was presented, confirmed, and sold off in the same session. The gap between those two reactions is what a competitive oncology market looks like when the treatment bar is finally rising.
Primary sources
- Business Wire announcement of the REZILIENT3 results for the trial data and regulatory plans.
- Yahoo Finance on the share decline for the market reaction.
- Fierce Biotech on the six-month benefit for the competitive context.